Tag: News
-
Finalists: OBN Awards 2025
Cellestial Health has been honoured as one of the top four companies in the BioSeed “Ones to Watch” category: https://obn.glueup.com/event/obn-awards-2025-128684/2025-finalists-announced.html#2025-finalists-announced The Awards, now in the 17th year, celebrate innovation and outstanding achievement across the Life Sciences industry. Being the company “to watch” is thrilling and prestigious, but also comes with a weight of expectation and…
-
Finalists: Cambridge Independent Business Awards 2025
For the second year now, Cambridge Independent newspaper hosts a prestigious Business Awards ceremony, celebrating businesses of all sectors and sizes from the Cambridgeshire region in a number of categories. Paul Brackley, Editor and Chair of the judging panel, comments in the latest article: “We were impressed by the quality of entries and it was…
-
Cambridge Tech Week: Innovation Alley Shortlist
This week Cellestial Health has been named one of 47 finalists in the Innovation Alley pitching competition, part of the Cambridge Tech Week. A variety of sectors was represented including deeptech, climatetech, agritech, batterytech, and so much more, from Cambridge and all around the world. Companies of all sizes and from all (tech-related) sectors were…
-
Strategic Win: Preclinical Development Consultation with L2D
Cellestial Health is one of the preclinical-stage companies that was recently selected for a free consultation with the top experts at Leads to Development (L2D) regulatory consultancy, Jonathan Kearsey and Vincent Dubois. This will provide confidential guidance and advice on the path to the regulatory approval of the first Cellestial drug asset. As Nat Hastings,…
-
Finalists: JP Morgan Life Sciences Innovation Summit
Cellestial Health has been named as one of the 10 global finalists in the Second Annual Life Sciences Innovation Summit organised by J.P. Morgan Asset Management’s Life Sciences Private Capital and King Abdullah International Medical Research Center (كيمارك KAIMRC), alongside EpiBone, Inc., FimmCyte Therapeutics, Genethon NewCo, NanoPalm | نانو بالم, Neurenati Therapeutics, Rinri Therapeutics, Script Biosciences,…
-
OBN BioSeed: Raising Awareness
On Monday 9th of June, Dr Nat Hastings presented the developments and plans of Cellestial Health at the annual #BioSeed event, where pitches are delivered by companies looking for Seed funding. At the moment, Cellestial is only preparing for its Seed funding round. What are the benefits of our early discussion with the investor community?…
-
Cellestial Health Closes Pre-Seed Equity Round
Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease. The equity round was led by Zinc VC, with the latest investment…
-
New Collaboration Alert: o2h Discovery and Cellestial
Cellestial Health joins forces with o2h in drug discovery as an awardee of the latest Kickstrater Award. o2h discovery is a collaborative Contract Research Organisation which has an integrated drug discovery platform in Ahmedabad (India) and Cambridge (UK). o2h offer a multi-modality integrated drug discovery platform to support their collaborators developing the next generation of…
-
One Nucleus #BioWednesday: Ones to Watch
Cellestial Health team gather in person at the #BioWednesday event by One Nucleus after an evening of pitches and networking at Queen Mary Bioenterprises – as a largely virtual company, we are more used to seeing each other in 2D! Thank you to Tony Jones, Alicia Gailliez, and the whole team at One Nucleus for…
-
New Paper: Connexin43 is Downregulated in Human Parkinson’s
Translational research often commences in various models – cells, rodents, slice cultures.. But results from all of these rest on an 𝙖𝙨𝙨𝙪𝙢𝙥𝙩𝙞𝙤𝙣 that the underlying cause of the human disease is correctly replicated in the chosen model. There is no single easy way to prove this assumption, especially in a complex and often multi-factorial condition…